exRNAdisease

Entry Detail

---



General Information

Database ID: exR0269786 RNA Name: hsa-miR-373-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53788748 End Site(bp): 53788770 External Links: hsa-miR-373-3p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand VLDLR chr9 2621787 2660056 + USP24 chr1 55066359 55215364 - CELF2 chr10 10798397 11336675 + APP chr21 25880550 26171128 - KLHL28 chr14 44924319 45042322 - RGMA chr15 93035273 93089204 - PFN2 chr3 149964904 150050788 - FAM177A1 chr14 35044907 35113130 + MBP chr18 76978827 77133683 - CUL1 chr7 148697914 148801110 + MSL1 chr17 40121971 40136917 + RIT1 chr1 155897808 155911404 - ATXN1 chr6 16299112 16761491 - ZFAND4 chr10 45615500 45672780 - SETD7 chr4 139495941 139606699 - BAZ1B chr7 73440406 73522293 - AMPD2 chr1 109616104 109632053 + SLC16A14 chr2 230034982 230068993 - PHC3 chr3 170086732 170181749 - FAM222B chr17 28755978 28855232 - PLEKHM1 chr17 45435900 45490749 - SYAP1 chrX 16719612 16765340 + ARL4A chr7 12686856 12690958 + RACGAP1 chr12 49976923 50033136 - LONP2 chr16 48244300 48363122 + CLIP4 chr2 29097705 29189643 + ADAR chr1 154582057 154628013 - MAGI3 chr1 113390515 113685923 + NAA16 chr13 41311267 41377030 + CLOCK chr4 55427903 55546909 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.